Pharmacokinetics and disposition of various drug loaded biodegradable poly(lactide-Co-glycolide) (PLGA) nanoparticles

Current Drug Metabolism

Volumn 11, Issue 10, 2010, Pages 859-869

  Song, Xiangrong ^a   Zhao, Xia ^a   Zhou, Yan ^a   Li, Shuangzhi ^a   Ma, Qing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Analytical technique; Disposition; Distribution; In vivo behavior; Nanoparticles; Pharmacokinetics; PLGA

Indexed keywords

ALPHA TOCOPHEROL; ANTIGEN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BORTEZOMIB; CHITOSAN; DEXTRAN SULFATE; DOXORUBICIN; ELCATONIN; GREEN FLUORESCENT PROTEIN; INFLUENZA VACCINE; NANOPARTICLE; OLIGONUCLEOTIDE; OVALBUMIN; PACLITAXEL; PEPTIDE; POLY(LACTIDE CO GLYCOLIDE)NANOPARTICLE; POLYGLACTIN; PROTEIN; RECOMBINANT GROWTH FACTOR; RECOMBINANT PROTEIN; TAMOXIFEN; TAMOXIFEN CITRATE; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VASCULOTROPIN INHIBITOR; VINCRISTINE; WHEAT GERM AGGLUTININ;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIODEGRADATION; BREAST CANCER; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; EMULSION; ENDOCYTOSIS; GENE TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNIZATION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INJECTION; LIVER TOXICITY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PEYER PATCH; PHARMACOLOGICAL PARAMETERS; SUBRETINAL NEOVASCULARIZATION; TOXOPLASMOSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYGLACTIN 910; TISSUE DISTRIBUTION;

EID: 79851468813     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010794479682     Document Type: Article

References (171)

1. Wise, D. L. In: Encyclopedic Handbook of Biomaterials and Bioengineering; Ed.; Marcel Dekker: New York, 1995; Vol. pp. 1015-1054.
2. Toro, R. D.; Betti, V.; Spampinato, S. Biocompatibility and integrin mediated adhesion of human osteoblasts to PLGA copolymers. Eur. J. Pharm. Sci., 2004, 21, 161-169. (Pubitemid 38156153)
3. Jain, R. A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials, 2000, 21, 2475-2490.
4. Vert, M. In: The Complexity of PLAGA-Based Drug Delivery Systems, Proceedings of the International Conference on Advances in Controlled Delivery, Baltimore, MD, 1996; Ed. Eds.; Baltimore, MD, 1996; pp. 32-36.
5. Jalil, R.; Nixon, J. R. Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J. Microencapsul., 1990, 7, 297-325. (Pubitemid 20336774)
6. Chasin, M.; Langer, R. In: Biodegradable Polymers as Drug Delivery Systems; Ed.; Marcel Dekker: New York, 1990; Vol. pp. 1-41.
7. Kitchell, J. P.; Wise, D. L. Poly (lactic/glycolic acid) biodegradable drug-polymermatrix systems. Methods Enzymol, 1985, 112, 436-448. (Pubitemid 15036597)
8. Cohen, S.; Alonso, M. J.; Langer, R. Novel approaches to controlled release antigen delivery. Int. J. Technol. Assess., 1994, 10(1), 121-130. (Pubitemid 24048626)
9. Chasin, M.; Langer, R. In: Biodegradable Polymers as Drug Delivery Systems; Ed.; Marcel Dekker: New York, 1990; Vol. pp. 1-41.
10. Tice, T. R.; Cowsar, D. R. Biodegradable controlled-release parenteral systems. Pharm. Technol., 1984, 11, 26-35.
11. Brady, J. M.; Cutright, D. E.; Miller, R. A.; Battistone, G. C. Resorption rate, route of elimination and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J. Biomed. Mater. Res., 1973, 7, 155-166.
12. Han, B.; Wang, H. T.; Liu, H. L.; Hong, H.; Wei, L.; Shang, Z. H. preparation of pingyangmycin PLGA microspheres and related in vitro/in vivo studies. Int. J. Pharm., 2010, 398 (1-2), 130-136.
13. Sun, F.; Sui, C.; Teng, L.; Liu, X.; Teng, L.; Meng, Q.; Li, Y. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. Int. J. Pharm., 2010, 397 (1-2), 44-49.
14. Tian, J. Y.; Sun, X. Q.; Chen, X. G., Yu, J.; Qu, L. Y.; Wang, L. C. The formulation and immunization of oral poly (DL-lactide-coglycolide) microcapsules containing a plasmid vaccine against lymphocystis disease virus in Japanese flounder (Paralichthys olivaceus). Int. Immunopharmacol., 2008, 8, 900-908.
15. Farahidah, M.; Christopher, F. W. PLGA microcapsules with novel dimpled surfaces for pulmonary delivery of DNA. Int. J. Pharm., 2006, 311 (1-2), 97-107.
16. Son, S.; Lee, W. R.; Joung, Y. K.; Kwon, M. H.; Kim, Y. S.; Park, K. D. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int. J. Pharm., 2009, 368, 178-185.
17. Javadzadeh, Y.; Ahadi, F.; Davaran, S.; Mohammadi, G.; Sabzevari, A.; Adibkia, K. Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. Colloids. Surface. B., 2010, 81(2), 498-502.
18. Wang, C. H.; Wang, W. Y.; Meyer, R. F.; Liang, Y. L.; Winey, K. I.; Siegel, S. J. A rapid method for creating drug implants: Translating laboratory-based methods into a scable manufacturing process. J. Biomed. Res. B., 2010, 93(2), 562-572.
19. Siegel, S. J.; Kahn, J. B.; Metzger, K.; Winey, K. I.; Werner, K.; Dan, N. Effect of drug type on the degradation rate of PLGA matrices. Eur. J. Pharm. Biopharm., 2006, 64(3), 287-293. (Pubitemid 44585214)
20. Wischke, C.; Zhang, Y.; Mittal, S.; Schwendeman, S. P. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide. Pharm. Res., 2010, 27(10), 2063-2074.
21. Liu, Q.; Zhang, H.; Zhou, G.; Xie, S.; Zou, H.; Yu, Y.; Li, G.; Sun, D.; Zhang, G.; Lu, Y.; Zhong, Y. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly (lactide-coglycolide) implants. Int. J. Pharm., 2009, 397 (1-2), 122-129.
22. Loo, S. C.; Tan, Z. Y.; Chow, Y. J.; Lin, S. L. Drug release from irradiated PLGA and PLLA multi-layered films. J. Pharm. Sci., 2010, 99(7), 3060-3071.
23. Xie, J.; Tan, J. C.; Wang, C. H. Biodegradable films developed by electrospray disposition for sustained drug delivery. J. Pharm. Sci., 2008, 97(8), 3109-3122.
24. Shen, H.; Hu, X.; Yang, F.; Bei, J.; Wang, S. The bioactivity of rhBMP-2 immobilized poly (lactide-co-glycolide) scaffolds. Biomaterials, 2009, 30(18), 3150-3157.
25. Wang, G. J.; Lin, Y. C.; Hsu, S. H. The fabrication of PLGA microvessel scaffolds with nano-patterned inner walls. Biomed. Microdevices., 2010, 12(5), 841-848.
26. Mooney, D. J.; Sano, K.; Kaufmann, P. M.; Majahod, K.; Schloo, B.; Vacanti, J. P.; Langer, R. Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges. J. Biomed. Mater. Res., 1997, 37, 413-420. (Pubitemid 27481456)
27. Eiselt, P.; Kim, B. S.; Chacko, B.; Isenberg, B.; Peters, M. C.; Greene, K. G.; Roland, W. D.; Loebsack, A. B.; Burg, K. J.; Culberson, C.; Halberstadt, C. R.; Holder, W. D.; Mooney, D. J. Development of technologies aiding large-tissue engineering. Biotechnol. Prog., 1988, 14, 134-140.
28. Govender, T.; Stolnik, S.; Garnett, M. C.; Illum, L.; Davis, S. S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control Release, 1999, 57, 171-185. (Pubitemid 29062869)
29. Jain, R. A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials, 2000, 21, 2475-2490.
30. Kim, D. H.; Martin, C. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials, 2006, 27, 3031-3037.
31. Gwak, S. J.; Kim, B. S. Poly (lactic-co-glycolic acid) nanosphere as a vehicle for gene delivery to human cord blood-derived mesenchymal stem cells: comparison with polyethylenimine. Biotechnol. Lett., 2008, 30, 1177-1182.
32. Mundargi, R. C.; Babu, V. R.; Rangaswamy, V.; Patel, P.; Aminabhavi, T. M. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J. Control Release, 2008, 125(3), 193-209.
33. Wischke, C.; Schwendeman, S. P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm., 2008, 364, 298-327.
34. Soppimath, K. S.; Aminabhavi, T. M.; Kulkarni, A. R.; Rudzinski, W. E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control Release, 2001, 70, 1-20. (Pubitemid 32144788)
35. Labhasetwar, V. Nanoparticles for drug delivery. Pharm. News, 1997, 4, 28-31.
36. Chakravarthi, S. S.; De, S.; Miller, D. W.; Robinson, D. H. Comparison of anti-tumor efficacy of paclitaxel delivered in nano-and microparticles. Int. J. Pharm., 2010, 383 (1-2), 37-44.
37. Desai, M. P.; Labhasetwar, V.; Walter, E.; Levy, R. J.; Amidon, G. L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res., 1997, 14, 1568-1573. (Pubitemid 28009208)
38. Zauner, W.; Farrow, N. A.; Haines, A. M. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J. Control. Release, 2001, 71, 39-51. (Pubitemid 32195440)
39. Kroll, R. A.; Pagel, M. A.; Muldoon, L. L.; Goldstein, S. R.; Fiamengo, S. A.; Neuwelt, E. A. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery, 1998, 43, 879-886.
40. Sahoo, S. K.; Panyam, J.; Prabha, S.; Labhasetwar, V. Residual polyvinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control Release, 2002, 82, 105-114. (Pubitemid 34775052)
41. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55, 329-347. (Pubitemid 36297053)
42. Ohashi, K.; Kabasawa, T.; Ozeki, T.; Okada, H. One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticlecontaining mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release, 2009, 135(1), 19-24.
43. Cohen-Sela, E.; Chomy, M.; Koroukhov, N.; Danenberg, H. D.; Golomb, G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J. Control Release, 2009, 133(2), 90-95.
44. Yallapu, M. M.; Gupta, B. K.; Jaggi, M.; Chauhan, S. C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J. Colloid Interface Sci., 2010, 351(1), 19-29.
45. Ravi Kumar, M. N. V.; Bakowsky, U.; Lehr, C. M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials, 2004, 25, 1771-1777. (Pubitemid 38102253)
46. Bala, I.; Hariharan, S.; Ravi Kumar, M. N. V. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Sys., 2004, 21, 387-422. (Pubitemid 41647578)
47. Choi, S. H.; Park, T. G. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method. Int. J. Pharm., 2006, 311, 223-228.
48. Chong, C. S. W.; Cao, M.; Wong, W. W.; Fischer, K. P.; Addison, W. R.; Kwon, G. S.; Tyrrell, D. L.; Samuel, John.. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release, 2005, 102, 85-89.
49. Lamprecht, A.; Ubrich, N.; Hombreiro Pérez, M.; Lehr, CM.; Hoffman, M.; Maincent, P. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int. J. Pharm., 2000, 196, 177-182. (Pubitemid 30105738)
50. Budhian, A.; Siegel, S. J.; Winey, K. I. Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int. J. Pharm., 2007, 336, 367-375. (Pubitemid 46670649)
51. Teixeira, M.; Alonsoc, M. J.; Pinto, M. M. M. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur. J. Pharm. Biopharm., 2005, 59, 491-500. (Pubitemid 40347293)
52. Song, X. R.; Zhao, Y.; Wu, W. B.; Bi, Y. Q.; Cai, Z.; Chen, Q. H.; Li, Y. B.; Hou, S. X. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int. J. Pharm., 2008, 350 (1-2), 320-329. (Pubitemid 351146679)
53. Niwa, T.; Takeuchi, H.; Hino, T.; Kunou, N.; Kawashima, Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with D, L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Release, 1993, 25, 89-98. (Pubitemid 23168633)
54. Niwa, T.; Takeuchi, H.; Hino, T.; Kunou, N.; Kawashima, Y. In vitro drug release behavior of D, L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. Sci., 1994, 83(5), 727-732. (Pubitemid 24219829)
55. Jin, C.; Bai, L.; Wu, H.; Song, W.; Guo, G.; Dou, K. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm. Res., 2009, 26(7), 1776-1784.
56. Tewes, F.; Munnier, E.; Antoon, B.; Ngaboni, O. L.; Cohen-Jonathan, S.; Marchais, H.; Douziech-Eyrolles, L.; Soucé, M.; Dubois, P.; Chourpa, I. Comparative study of doxorubicin-loaded poly (lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods. Eur. J. Pharm. Biopharm., 2007, 66(3), 488-492. (Pubitemid 46756231)
57. Barichello, J. M.; Morishita, M.; Takayama, K.; Nagai, T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev. Ind. Pharm., 1999, 25, 471-476. (Pubitemid 29159426)
58. Bilati, U.; Allémann, E.; Doelker, E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur. J. Pharm. Sci., 2005, 24, 67-75. (Pubitemid 40051288)
59. Cirpanli, Y.; Bilensoy, E.; Lale Doǧan A.; Caliş, S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur. J. Pharm. Biopharm., 2009, 73(1), 82-89.
60. Gan, L. C.; Hou, S. X.; Bi, Y. Q.; Wang, C. G.; Wang, X. C.; Chen, Q. X. Comparison of two preparation methods applied in tanshinone II (A)-loaded PLGA nanoparticles. Zhongguo Zhong Yao Za Zhi, 2007, 32(7), 578-581.
61. Leroux, J. C.; AlleHmann, E.; De Jaeghere, F.; Doelker, E.; Gurny, R. Biodegradable nanoparticles-From sustained release formulations to improved site specific drug delivery. J. Control. Release, 1996, 39, 339-350. (Pubitemid 26195837)
62. Song, X. R.; Cai, Z.; Zheng, Y.; He, G.; Cui, F. Y.; Gong, D. Q.; Hou, S. X.; Xiong, S. J.; Lei, X. J.; Wei, Y. Q. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci., 2009, 37 (3-4), 300-305.
63. Saxena, V.; Sadoqi, M.; Shao, J. Indocyanine green-loaded biodegradable nanoparticles, preparation, physicochemical characterization and in vitro release. Int. J. Pharm., 2004, 278, 293-301. (Pubitemid 38759502)
64. Niwa, T.; Takeuchi, H.; Hino, T.; Nohara, M.; Kawashima, Y. Biodegradable submicron carriers for peptide drugs, preparation of DL-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate by a novel emulsion-phase separation method in an oil system. Int. J. Pharm., 1995, 121, 45-54.
65. Kakizawa, Y.; Nishio, R.; Hirano, T.; Koshi, Y.; Nukiwa, M.; Koiwa, M.; Michizoe, J.; Ida, N. Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanoparticles. J. Control. Release, 2010, 142(1), 8-13.
66. ® RS100 or RL100/PLGA nanoparticles. Int. J. Pharm., 2006, 314, 72-78.
67. Ubrich, N.; Bouillot, P.; Pellerin, C.; Hoffman, M.; Maincent, P. Preparation and characterization of propranolol hydrochloride nanoparticles, a comparative study. J. Control. Release, 2004, 97, 291-300. (Pubitemid 38759486)
68. Cui, F. Y.; Song, X. R.; Li, Z. Y.; Li, S. Z.; Mu, B.; Mao, Y. Q.; Wei, Y. Q.; Yang, L. The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma. Oncol. Rep., 2010, 24(3), 661-668.
69. Kawashima, Y. Insulin delivery by using PLGA nanoparticulate system. Nippon Rinsho, 2006, 64(2), 301-307.
70. Bittner, B.; Ronneberger, B.; Zange, R.; Volland, C.; Anderson, J. M.; Kissel, T. Bovine serum albumin loaded poly (lactide-coglycolide) microspheres: the influence of polymer purity on particle characteristics. J. Microencapsul, 1998, 15, 495-514. (Pubitemid 28288738)
71. Johansen, P.; Men, Y.; Audran, R.; Corradin, G.; Merkle, H. P.; Gander, B. Improving stability & release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res., 1998, 15, 1103-1110. (Pubitemid 28356930)
72. Li, Y.; Ogris, M.; Pelisek, J.; Röedl, W. Stability and release characteristics of poly (D, L-lactide-co-glycolide) encapsulated CaPi-DNA coprecipitation. Int. J. Pharm., 2004, 269(1), 61-70. (Pubitemid 38032823)
73. Sheetal, S. P.; Robert, D. T.; Todd, M. P. Poly (ethylene glycol) - Modified Proteins: Implications for Poly (lactide-co-glycolide) - Based Microsphere Delivery. AAPS J., 2009, 11(1), 88-98.
74. Patil, Y. B.; Swaminathan, S. K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials, 2010, 31(2), 358-365.
75. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release, 2009, 136(1), 21-29.
76. Song, X. R.; Zhao, Y.; Hou, S. X.; Wu, W. B.; Bi, Y. Q.; Xu, F. Y.; Zhao, R. L.; He, J. Y.; Cai, Z.; Li, Y. B.; Chen, Q. H. Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug en-trapment efficiency. Eur. J. Pharm. Biopharm., 2008, 69(2), 445-453.
77. Song, X. R.; Cai, Z.; Zheng, Y.; He, G.; Cui, F. Y.; Gong D. Q.; Hou, S. X.; Xiong, S. J.; Lei, X. J.; Wei, Y. Q. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci., 2009 (3-4), 37, 300-305
78. Yadav, K. S.; Chuttani, K.; Mishra, A. K.; Sawant, K. K. Long Circulating Nanoparticles of Etoposide Using PLGA-MPEG and PLGA-Pluronic Block Copolymers: Characterization, Drug-Release, Blood-Clearance, and Biodistribution Studies. Drug Develop. RES., 2010, 71(4), 228-239.
79. Fay, F.; Quinn, D. J.; Gilmore, B. F.; McCarron, P. A.; Scott, C. J. Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials, 2010, 31(14), 4214-4222.
80. Rajapaksa, T. E.; Stover-Hamer, M.; Fernandez, X.; Eckelhoefer, H. A. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J. Control. Release, 2010, 142(2), 196-205.
81. Tahara, K.; Samura, S.; Tsuji, K.; Yamamoto, H.; Tsukada, Y.; Bando, Y.; Tsujimoto, H.; Morishita, R.; Kawashima, Y. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly (d.; l-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials, 2010, doi:10.1016/j.biomaterials.2010.1009.1034.
82. Zhao, L. Y.; Feng, S. S. Enhanced Oral Bioavailability of Paclitaxel Formulated in Vitamin E-TPGS Emulsified Nanoparticles of Biodegradable Polymers: In Vitro and In Vivo Studies. J. Pharm. Sci., 2010, 99(8), 3552-3560.
83. Fattal, E.; Pecquet, S.; Couvreur, P.; Andremont, A. Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int. J. Pharm., 2002, 242 (1-2), 15-24.
84. Shakweh, M.; Besnard, M.; Nicolas, V.; Fattal, E. Poly (lactide-coglycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur. J. Pharm. Biopharm., 2005, 61 (1-2), 1-13. (Pubitemid 41096683)
85. Florence, A. T. The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm. Res., 1997, 14, 259-266. (Pubitemid 27160935)
86. Jayanth, P.; Vinod, L. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55, 329-347.
87. Desai, M. P.; Labhasetwar, V.; Amidon, G. L.; Levy, R. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. J. Pharm. Res., 1996, 13, 1838-1845. (Pubitemid 27034116)
88. Jani, P.; Halbert, G. W.; Langridge, J.; Florence, A. T. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol., 1989, 41, 809-812. (Pubitemid 20112141)
89. Mathiowitz, E.; Jacob, J. S.; Jong, Y. S.; Carino, G. P.; Chickering, D. E.; Chaturvedi, P.; Santos, C. A.; Vijayaraghavan, K.; Montgomery, S.; Bassett, M.; Morrell, C. Biologically erodable microspheres as potential oral drug delivery systems. Nature, 1997, 386 (410-414). (Pubitemid 27154483)
90. Damgé, C.; Aprahamian, M.; Humbert, W.; Pinget, M. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol., 2000, 52(9), 1049-1056.
91. Limpanussorn, J.; Simon, L.; Dayan, A. D. Transepithelial transport of large particles in rat: a new model for the quantitative study of particle uptake,. J. Pharm. Pharmacol., 1998, 50(7), 753-760. (Pubitemid 28379269)
92. Jung, T.; Kamm, W.; Breitenbach, A.; Kaiserling, E.; Xiao, J. X.; Kissel, T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm., 2000, 50, 147-160. (Pubitemid 30326694)
93. Yin, Y. S.; Chen, D. W.; Qiao, M. X.; Lu, Z.; Hu, H. Y. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J. Control. Release, 2006, 116, 337-345. (Pubitemid 44827411)
94. Jain, A. K.; Swarnakar, N. K.; Godugu, C., Singh, R. P.; Jain, S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials, 2010, doi:10.1016/j.biomaterials.2010. 1009.1037
95. Ling, G.; Zhang, P.; Zhang, W.; Sun, J.; Meng, X.; Qin, Y.; Deng, Y.; He, Z. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J. Control. Release, 2010, 148(2), 241-248.
96. Takeuchi, H.; Yamamoto, H.; Kawashima, Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Deliv. Rev., 2001, 47, 39-54. (Pubitemid 32209231)
97. Yin, Y.; Chen, D.; Qiao, M.; Wei, X.; Hu, H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J. Control. Release, 2007, 123(1), 27-38. (Pubitemid 47444385)
98. Ponchel, G.; Irache, J. M. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev., 1998, 34, 191-219. (Pubitemid 28535112)
99. Kawashima, Y.; Yamamoto, H.; Takeuchi, H.; Kuno, Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol., 2000, 5(1), 77-85. (Pubitemid 30069202)
100. Nagata, Y.; Burger, M. M. Wheat germ agglutinin molecular characteristics and specificity for sugar binding. J. Biol. Chem., 1974, 249, 3116-3122.
101. Gabor, F.; Wirth, M.; Jurkovich, B.; Haberl, I.; Theyer, G.; Walcher, G.; Hamilton, G. Lectin-mediated bioadhesion: proteolytic stability and bindingcharacteristics of wheat germ agglutinin and solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes. J. Control. Release, 1997, 49, 27-37. (Pubitemid 27417898)
102. Weissenböck, A.; Wirth, M.; Gabor, F. WGA-grafted PLGA nanospheres:preparation and association with Caco-2 single cells. J. Control. Release, 2004, 99, 383-392. (Pubitemid 39296907)
103. Walter, F.; Schöll, I.; Untersmayr, E.; Ellinger, A.; Boltz-Nitulescu, G.; Scheiner, O.; Gabor, F.; Jensen-Jarolim, E. Functionalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. Biochem. Biophy. Res. Com., 2004, 315, 281-287. (Pubitemid 38183105)
104. Mo, Y.; Lim, L. Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J. Control. Release, 2005, 107, 30-42. (Pubitemid 41253700)
105. Brayden, D. J.; Jepson, M. A.; Baird, A. W. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov. Today, 2005, 10, 1145-1157. (Pubitemid 41334666)
106. Kraehenbuhl, J. P.; Neutra, M. R. Epithelial M cells: differentiation and function. Annu. Rev. Cell. Dev. Biol., 2000, 16, 301-322.
107. Jang, M. H.; Kweon, M. N.; Watani, K. I.; Yamamoto, M.; Terahara, K.; Sasakawa, C.; Suzuki, T.; Nochi, T.; Yokota, Y.; Rennert, P. D.; Hiroi, T.; Tamagawa, H.; Iijima, H.; Kunisawa, J.; Yuki, Y.; Kiyono, H. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc. Natl. Acad. Sci. USA, 2004, 101, 6110-6115. (Pubitemid 38520536)
108. Neutra, M. R. Current concepts in mucosal immunity. V role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am. J. Physiol., 1998, 274, G785-G791.
109. Siebers, A., Finlay, B. B. M cells and the pathogenesis of mucosal and systemic infections. Trends Microbiol., 1996, 4, 22-29. (Pubitemid 26032167)
110. Garinot, M.; Fiévez, V.; Pourcelle, V.; Stoffelbach, F.; des Rieux, A.; Plapied, L.; Theate, I.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Schneider, Y. J.; Préat, V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release, 2007, 120(3), 195-204. (Pubitemid 47061488)
111. Gullberg, E.; Leonard, M.; Karlsson, J.; Hopkins, A. M.; Brayden, D.; Baird, A. W.; Artursson, P. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun., 2000, 279, 808-813. (Pubitemid 32042860)
112. Gullberg, E.; Keita, A. V.; Salim, S. Y.; Andersson, M.; Caldwell, K. D.; Soderholm, J. D.; Artursson, P. Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J. Pharmacol. Exp. Ther., 2006, 319, 632-639.
113. Kuo, W. L.; Lee, L. Y.; Wu, C. M.; Wang, C. C.; Yu, J. S.; Liang, Y.; Lo, C. H.; Huang, K. H.; Hwang, T. L. Differential expression of claudin-4 between intestinal and diffuse-type gastric cancer. Oncol. Rep., 2006, 16(4), 729-734.
114. Lo, D.; Tynan, W.; Dickerson, J.; Scharf, M.; Cooper, J.; Byrne, D.; Brayden, D.; Higgins, L.; Evans, C. O'Mahony, D. J. Cell culture modeling of specialized tissue: identification of genes expressed specifically by follicle-associated epithelium of Peyer's patch by expression profiling of Caco-2/Raji co-cultures. Int. Immunol., 2004, 16(1), 91-99. (Pubitemid 38054630)
115. Rahner, C.; Mitic, L. L.; Anderson, J. M. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology, 2001, 120(2), 411-422. (Pubitemid 32147639)
116. Ling, J.; Liao, H.; Clark, R.; Wong, M. S.; Lo, D. D. Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J. Biol. Chem., 2008, 283(45), 30585-30595.
117. Coombes, A. G.; Yeh, M. K.; Lavelle, E. C.; Davis, S. S. The control of protein release from poly (DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J. Control. Release 1998, 52(3), 311-320. (Pubitemid 28135259)
118. Aukunuru, J. V.; Ayalasomayajula, S. P.; Kompella, U. B. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J. Pharm. Pharmacol., 2003, 55(9), 1199-1206. (Pubitemid 37180005)
119. Bejjani, R. A.; BenEzra, D.; Cohen, H.; Rieger, J.; Andrieu, C.; Jeanny, J. C.; Gollomb, G.; Behar-Cohen, F. F. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis., 2005, 11, 124-132. (Pubitemid 41358300)
120. Singh, S. R.; Grossniklaus, H. E.; Kang, S. J.; Edelhauser, H. F.; Ambati, B. K.; Kompella, U. B. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther., 2009, 16(5), 645-659.
121. Friedlander, M.; Theesfeld, C. L.; Sugita, M.; Fruttiger, M.; Thomas, M. A.; Chang, S.; Cheresh, D. A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA, 1996, 93(18), 9764-9769. (Pubitemid 26296683)
122. He, X.; Hahn, P.; Iacovelli, J.; Wong, R.; King, C.; Bhisitkul, R.; Massaro-Giordano, M.; Dunaief, J. L. Iron homeostasis and toxicity in retinal degeneration. Prog. Retin. Eye Res., 2007, 26, 649-673. (Pubitemid 47615564)
123. Chowers, I.; Wong, R.; Dentchev, T.; Farkas, R. H.; Iacovelli, J.; Gunatilaka, T. L.; Medeiros, N. E.; Presley, J. B.; Campochiaro, P. A.; Curcio, C. A.; Dunaief, J. L.; Zack, D. J. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci., 2006, 47, 2135-2140. (Pubitemid 46768298)
124. Lemoine, D.; Deschuyteneer, M.; Hogge, F.; Préat, V. Intranasal immunization against influenza virus using polymeric particles. J. Biomater. Sci. Polym. Ed., 1999, 10(8), 805-825. (Pubitemid 29408386)
125. Jepson, M. A.; Clark, M. A.; Foster, N.; Mason, C. M.; Bennett, M. K.; Simmons, N. L.; Hirst, B. H. Targeting to intestinal M cells. J. Anat., 1996, 189 (Pt 3), 507-516. (Pubitemid 27011003)
126. Stanley, A. C.; Buxton, D.; Innes, E. A.; Huntley, J. F. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine, 2004, 22 (29-30), 3929-3941. (Pubitemid 39208755)
127. Tsapis, N.; Bennett, D.; Jackson, B.; Weitz, D. A.; Edwards, D. A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Nat. Acad. Sci. USA, 2002, 99, 12001-12005.
128. Jensen, D. M. K.; Cun, D.; Maltesen, M. J.; Frokjaer, S.; Nielsen, H. M.; Foged, C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release, 2010, 142(1), 138-145.
129. Dailey, L. A.; Fink, N. L.; Gessler, T.; Schemehl, T.; Wittmar, M.; Kissel, T.; Seeger, W. Investigation of the proinflammatory potential biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol., 2006, 215, 100-108. (Pubitemid 44118400)
130. Oberdörster, G. Pulmonary effects of inhaled ultrafine particles. Int. Arch. Occup. Environ. Health, 2001, 74, 1-8. (Pubitemid 32123735)
131. Hamoir, J.; Nemmar, A.; Halloy, D.; Wirth, D.; Vincke, G.; Vanderplasschen, A.; Nemery, B.; Gustin, P. Effect of polystyrene particles on lung microvascular permeability in isolated perfused rabbit lungs: role of size and surface properties. Toxicol. Appl. Pharmacol., 2003, 190, 278-285. (Pubitemid 36937218)
132. Bivas-Benita, M.; Romeijn, S.; Junginger, H. E.; Borchard, G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm., 2004, 58, 1-6. (Pubitemid 38780998)
133. Vij, N.; Min, T.; Marasigan, R.; Belcher, C. N.; Mazur, S.; Ding, H.; Yong, K. T.; Roy, I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnology, 2010, doi: 10.1186/1477-3155-1188-1122.
134. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60(15), 1615-1626.
135. Goldberg, E. P.; Hadba, A. R.; Almond, B. A.; Marotta, J. S. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J. Pharm. Pharmacol., 2002, 54(2), 159-180. (Pubitemid 34150053)
136. Gref, R.; Minamitake, Y.; Peracchia, M. T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263(5153), 1600-1603. (Pubitemid 24128361)
137. Stolnik, S.; Dunn, S. E.; Garnett, M. C.; Davis, M. C.; Coombes, A. G.; Taylor, D. C.; Irving, M. P.; Purkiss, S. C.; Tadros, T. F.; Davis, S. S.; Illum, L. Surface modiffication of poly (lactide-coglycolide) nanospheres by biodegradable poly (lactide)}poly (ethylene glycol) copolymers. Pharm. Res., 1994, 11(12), 1800-1808.
138. Mohamed, F.; van der Walle, C. F. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sci., 2008, 97(1), 71-87.
139. He, Q.; Liu, J.; Sun, X.; Zhang, Z. R. Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells. World J. Gastroenterol, 2004, 10(5), 660-663. (Pubitemid 38351531)
140. Haley, B.; Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol., 2008, 26(1), 57-64.
141. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA, 1998, 95(8), 4607-4612. (Pubitemid 28207960)
142. Rubin, P.; Casarett, G. Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors. Clin. Radiol., 1996, 17(4), 346-355.
143. Shubik, P. Vascularization of tumors: a review. J. Cancer Res. Clin. Oncol., 1982, 103(3), 211-226. (Pubitemid 12099234)
144. Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 1971, 133(2), 275-288.
145. Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N. K. A PEGylated dendritic
146. Fawaz, F.; Bonini, F.; Guyot, M.; Lagueny, A. M.; Fessi, H.; Devissaguet, J. P. Influence of poly (DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit. Pharm. Res., 1993, 10(5), 750-756. (Pubitemid 23152324)
147. Gref, R.; Lück, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Müller, R. H. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces, 2000, 18 (3-4), 301-313. (Pubitemid 30479870)
148. Otsuka, H.; Nagasaki, Y.; Kataoka, K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev., 2003, 55(3), 403-419. (Pubitemid 36293792)
149. Danhier, F.; Lecouturier, N.; Vroman, B.; Jérôme, C.; Marchand-Brynaert, J.; Feron, O.; Préat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control. Release, 2009, 133(1), 11-17.
150. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M. A.; Forni, F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release, 2005, 108(1), 84-96. (Pubitemid 41476677)
151. Dufes, C.; Keith, W. N.; Bilsland, A.; Proutski, I.; Uchegbu, J. F.; Schatzlein, A. G. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res., 2005, 65(18), 8079-8084. (Pubitemid 41330568)
152. Costantino, L.; Gandolfi, F.; Bossy-Nobs, L.; Tosi, G.; Gurny, R.; Rivasi, F.; Vandelli, M. A.; Forni, F. Nanoparticulate drug carriers based on hybrid poly (D, L-lactide-co-glycolide)-dendron structures. Biomaterials, 2006, 27, 4635-4645. (Pubitemid 43783224)
153. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C.. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28(5), 869-876. (Pubitemid 44667020)
154. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 1997, 3(1), 81-85. (Pubitemid 27079448)
155. Tachibana, R.; Harashima, H.; Shono, M.; Azumano, M.; Niwa, M.; Futaki, S.; Kiwada, H. Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking. Biochem. Biophys. Res. Comm., 1998, 251(2), 538-544. (Pubitemid 28505058)
156. Vasir, J. K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv. Drug Deliv. Rev., 2007, 59(8), 718-728. (Pubitemid 47320811)
157. Panyam, J.; Labhasetwar, V. Targeting intracellular targets. Curr. Drug Deliv., 2004, 1(3), 235-247.
158. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782.
159. Schwartz, H. S. A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem. Med., 1973, 7(3), 396-404.
160. Van Vunakis, H.; Langone, J. J.; Riceberg, L. J.; Levine, L. Radioimmunoassays for adriamycin and daunomycin. Cancer Res., 1974, 34(10), 2546-2552.
161. Zagotto, G.; Gatto, B.; Moro, S.; Sissi, C.; Palumbo, M. Anthracyclines: recent developments in their separation and quantitation. J. Chromatogr. B Biomed. Sci. Appl., 2001, 764 (1-2), 161-171. (Pubitemid 33044664)
162. Pierce, R. N.; Jatlow, P. I. Measurement of adriamycin (doxorubicin) and its metabolites in human-plasma using reversed-phase high-performance liquidchromatography and fluorescence detection. J. Chromatogr., 1979, 164(4), 471-478. (Pubitemid 10180883)
163. Mora, L.; Chumbimuni-Torres, K. Y.; Clawson, C.; Hernandez, L.; Zhang, L.; Wang, J. Real-time electrochemical monitoring of drug release from therapeutic nanoparticles. J. Control. Release, 2009, 140(1), 69-73.
164. Onuki, Y.; Jacobs, I.; Artemov, D.; Kato, Y. Noninvasive visualization of in vivo release and intratumoral distribution of surrogate MR contrast agent using the dual MR contrast technique. Biomaterials, 2010, 31(27), 7132-7138.
165. Kissinger, P. T. Amperometric and coulometric detectors for highperformance liquid-chromatography. Anal. Chem., 1977, 49, 447-452.
166. He, Q.; Yuan, W. M.; Liu, J.; Zhang, Z. R. Study on in vivo distribution of liver-targeting nanopaticles encapsulating thymidine kinase gene (TK gene) in mice. J. Mater. Sci: Mater. Med., 2008, 19, 559-565. (Pubitemid 351244028)
167. Lurie, I. S. Problems in using high performance liquid chromatography for drug analysis. J. Forensic Sci., 1984, 29(2), 607-610. (Pubitemid 14132884)
168. Tosi, G.; Rivasi, F.; Gandolfi, F.; Costantino, L.; Vandelli, M. A.; Forni, F. Conjugated poly (D, Llactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials, 2005, 26(19), 4189-4195. (Pubitemid 40138665)
169. Tung, C. H.; Bredow, S.; Mahmood, U.; Weissleder, R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug. Chem., 1999, 10(5), 892-896. (Pubitemid 29456379)
170. Weissleder, R.; Tung, C. H.; Mahmood, U.; Bogdanov, A. J. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat. Biotechnol., 1999, 17(4), 375-378. (Pubitemid 29166041)
171. * effect of iron particles. Magn. Reson. Med., 2009, 61(5), 1059-1065.